Related Experiment Video
Updated: Apr 24, 2026
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Advances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumors
Jenny Adamski1, Vijay Ramaswamy2, Annie Huang3
1Division of Haematology/Oncology, The Hospital for Sick Children 555 University Avenue Toronto, Ontario M5G 1X8 Canada.
Abstract:
Medulloblastoma and central nervous system (CNS)-primitive neuro-ectodermal tumors (PNETs) are a diverse group of entities which encompasses different pathological and clinical pictures. Initially divided based on histology and location, molecular insight is leading to new definitions and a change in the borders delineating these diseases, such that they become more divergent. Current treatment approaches consist of surgical resection, radiotherapy and intensive chemotherapy, dependent on age. Stratification is one risk factor shown to be prognostic and is divided into high- and average-risks. Outcomes with modern treatment regimens are good, particularly in average-risk medulloblastoma patients, but the cost of cure is high, with high rates of neurocognitive, endocrine and social dysfunction. The changing biological landscape, however, may allow for clearer prediction of tumor behavior, to better identify "good" and "bad" players within these groups. Discovery of subgroups with changes in dependent molecular pathways will also lead to the development of new specific targeted therapies. Presenting exciting opportunities, these advances may transform the treatment for some patients, revolutionizing therapy in the future. Several challenges, however, are yet to be faced and caution is needed not to abandon previously defined prognostic factors on the strength of thus far retrospective evidence. We are witnessing a new era of trials with biological stratification involving multiple subgroups and treatment arms, based on specific tumor-related targets. This review discusses the changing face of medulloblastoma and CNS-PNETs and how we move molecular advances into clinical trials that benefit patients.
Insights
Molecular insights are redefining medulloblastoma and CNS-primitive neuro-ectodermal tumors (PNETs). New targeted therapies and biological stratification promise improved outcomes, but challenges remain in integrating these advances into clinical practice.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Molecular Pathology
Background:
- Medulloblastoma and CNS-primitive neuro-ectodermal tumors (PNETs) are pathologically and clinically diverse central nervous system (CNS) malignancies.
- Historically classified by histology and location, recent molecular discoveries are refining disease definitions and highlighting their divergence.
- Current treatments involve surgery, radiotherapy, and chemotherapy, with risk stratification impacting prognosis.
Purpose of the Study:
- To review the evolving landscape of medulloblastoma and CNS-PNETs driven by molecular insights.
- To discuss the integration of molecular advances into clinical trials for improved patient outcomes.
- To highlight the potential of targeted therapies and biological stratification in transforming treatment paradigms.
Main Methods:
- Review of current literature on medulloblastoma and CNS-PNETs.
- Analysis of molecular pathways and their impact on disease classification and prognosis.
- Discussion of challenges and opportunities in translating molecular findings into clinical practice.
Main Results:
- Molecular insights are leading to a redefinition of medulloblastoma and CNS-PNETs, moving beyond traditional histological classifications.
- New molecular subgroups are being identified, offering potential for more accurate prognostication and targeted therapies.
- While modern treatments show good outcomes, they are associated with significant long-term toxicities.
Conclusions:
- The field is shifting towards biologically stratified clinical trials targeting specific molecular pathways.
- Advances in understanding tumor biology hold promise for developing novel, specific therapies for medulloblastoma and CNS-PNETs.
- Caution is advised in abandoning established prognostic factors until further evidence supports the clinical utility of new molecular markers.
